Calliditas Therapeutics AB (publ) provided revenue guidance for the year ending December 31, 2024. For the year, the company expects continued revenue growth: total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.7 SEK | -0.38% | +3.18% | -18.41% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.41% | 508M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |
- Stock Market
- Equities
- CALTX Stock
- News Calliditas Therapeutics AB
- Calliditas Therapeutics AB Provides Revenue Guidance for the Year Ending December 31, 2024